APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal 13-valent Conjugate Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pneumococcal 13-valent Conjugate Vaccine Market Analysis and Forecast 2026-2032

29 December 2025193 pages

Choose your research edition.

Industry ResearchPneumococcal 13-valent Conjugate Vaccine Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal 13-valent Conjugate Vaccine Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Pneumococcal 13-valent Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal 13-valent Conjugate Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal 13-valent Conjugate Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Pneumococcal 13-valent Conjugate Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pneumococcal 13-valent Conjugate Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Pneumococcal 13-valent Conjugate Vaccine include Pfizer, BIOKANGTAI and Walvax, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Pneumococcal 13-valent Conjugate Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pneumococcal 13-valent Conjugate Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Pneumococcal 13-valent Conjugate Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pneumococcal 13-valent Conjugate Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pneumococcal 13-valent Conjugate Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Pneumococcal 13-valent Conjugate Vaccine sales, projected growth trends, production technology, application and end-user industry.

Pneumococcal 13-valent Conjugate Vaccine Segment by Company

Pfizer

BIOKANGTAI

Walvax

Pneumococcal 13-valent Conjugate Vaccine Segment by Type

0.5ml

Other

Pneumococcal 13-valent Conjugate Vaccine Segment by Application

Hospital

Clinic

Pneumococcal 13-valent Conjugate Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal 13-valent Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal 13-valent Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal 13-valent Conjugate Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Pneumococcal 13-valent Conjugate Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Pneumococcal 13-valent Conjugate Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumococcal 13-valent Conjugate Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 0.5ml Major Manufacturers Table 3. Other Major Manufacturers Table 4. Global Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Pneumococcal 13-valent Conjugate Vaccine Industry Trends Table 8. Pneumococcal 13-valent Conjugate Vaccine Industry Drivers Table 9. Pneumococcal 13-valent Conjugate Vaccine Industry Opportunities and Challenges Table 10. Pneumococcal 13-valent Conjugate Vaccine Industry Restraints Table 11. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region (2021-2026) Table 15. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region (2027-2032) Table 16. Global Pneumococcal 13-valent Conjugate Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 17. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026) & (K Units) Table 18. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2027-2032) & (K Units) Table 19. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region (2021-2026) Table 20. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region (2027-2032) Table 21. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Manufacturers (2021-2026) Table 25. Global Pneumococcal 13-valent Conjugate Vaccine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Pneumococcal 13-valent Conjugate Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Pneumococcal 13-valent Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers, Product Type & Application Table 29. Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Pneumococcal 13-valent Conjugate Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2026) Table 36. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2027-2032) Table 37. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 38. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 39. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 40. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026) Table 41. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2027-2032) Table 42. Global Pneumococcal 13-valent Conjugate Vaccine Price by Type (2021-2026) & (US$/Unit) Table 43. Global Pneumococcal 13-valent Conjugate Vaccine Price by Type (2027-2032) & (US$/Unit) Table 44. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2021-2026) Table 48. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2027-2032) Table 49. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 50. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 51. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 52. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026) Table 53. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2027-2032) Table 54. Global Pneumococcal 13-valent Conjugate Vaccine Price by Application (2021-2026) & (US$/Unit) Table 55. Global Pneumococcal 13-valent Conjugate Vaccine Price by Application (2027-2032) & (US$/Unit) Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 60. Pfizer Recent Development Table 61. BIOKANGTAI Company Information Table 62. BIOKANGTAI Business Overview Table 63. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 65. BIOKANGTAI Recent Development Table 66. Walvax Company Information Table 67. Walvax Business Overview Table 68. Walvax Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 70. Walvax Recent Development Table 71. North America Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 72. North America Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 73. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 74. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 75. North America Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 76. North America Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 77. North America Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 78. North America Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 79. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 80. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 81. North America Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 82. North America Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 83. North America Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 84. North America Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 85. North America Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 86. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 87. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 88. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 89. North America Pneumococcal 13-valent Conjugate Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 90. North America Pneumococcal 13-valent Conjugate Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 91. United States Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 92. Canada Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 93. Mexico Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 94. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 97. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 98. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 99. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 100. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 101. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 102. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 103. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 104. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 105. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 106. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 108. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 109. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 110. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 111. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 112. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 113. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 114. Germany Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 115. France Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 116. U.K. Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 117. Italy Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 118. Russia Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 119. Spain Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 120. Netherlands Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 121. Switzerland Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 122. Sweden Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 123. Poland Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 124. China Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 125. China Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 126. China Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 127. China Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 128. China Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 129. China Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 130. China Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 131. China Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 132. China Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 133. China Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 134. China Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 135. China Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 136. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 137. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 138. Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 139. Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 140. Asia Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 141. Asia Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 142. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 143. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 144. Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 145. Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 146. Asia Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 147. Asia Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 148. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 150. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 151. Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 152. Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 153. Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 154. Asia Pneumococcal 13-valent Conjugate Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 155. Asia Pneumococcal 13-valent Conjugate Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 156. Japan Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 157. South Korea Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 158. India Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 159. Australia Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 160. Taiwan Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 161. Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 162. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 163. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 164. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 165. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 166. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 167. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 168. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 169. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 170. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 171. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 172. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 173. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 174. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 176. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 177. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 178. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 179. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 180. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 181. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 182. Brazil Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 183. Argentina Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 184. Chile Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 185. Colombia Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 186. Peru Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 187. Saudi Arabia Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 188. Israel Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 189. UAE Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 190. Turkey Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 191. Iran Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 192. Egypt Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 193. Key Raw Materials Table 194. Raw Materials Key Suppliers Table 195. Pneumococcal 13-valent Conjugate Vaccine Distributors List Table 196. Pneumococcal 13-valent Conjugate Vaccine Customers List Table 197. Research Programs/Design for This Report Table 198. Authors List of This Report Table 199. Secondary Sources Table 200. Primary Sources List of Figures Figure 1. Pneumococcal 13-valent Conjugate Vaccine Image Figure 2. Global Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal 13-valent Conjugate Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. 0.5ml Image Figure 5. Other Image Figure 6. Global Pneumococcal 13-valent Conjugate Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Pneumococcal 13-valent Conjugate Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Global Pneumococcal 13-valent Conjugate Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 12. Global Pneumococcal 13-valent Conjugate Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region (2021-2032) Figure 15. Global Pneumococcal 13-valent Conjugate Vaccine Sales (2021-2032) & (K Units) Figure 16. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 17. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Pneumococcal 13-valent Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 19. Europe Pneumococcal 13-valent Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 20. China Pneumococcal 13-valent Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 21. Asia (Excluding China) Pneumococcal 13-valent Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 22. South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 23. Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2032) Figure 29. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2032) Figure 32. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2021-2032) Figure 35. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2032) Figure 38. North America Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 39. North America Pneumococcal 13-valent Conjugate Vaccine Sales Share by Type (2021-2032) Figure 40. North America Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 41. North America Pneumococcal 13-valent Conjugate Vaccine Sales Share by Application (2021-2032) Figure 42. North America Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 43. North America Pneumococcal 13-valent Conjugate Vaccine Sales Share by Country (2021-2032) Figure 44. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 45. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Share by Type (2021-2032) Figure 46. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 47. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Share by Application (2021-2032) Figure 48. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 49. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Share by Country (2021-2032) Figure 50. China Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 51. China Pneumococcal 13-valent Conjugate Vaccine Sales Share by Type (2021-2032) Figure 52. China Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 53. China Pneumococcal 13-valent Conjugate Vaccine Sales Share by Application (2021-2032) Figure 54. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 55. Asia Pneumococcal 13-valent Conjugate Vaccine Sales Share by Type (2021-2032) Figure 56. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 57. Asia Pneumococcal 13-valent Conjugate Vaccine Sales Share by Application (2021-2032) Figure 58. Asia Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 59. Asia Pneumococcal 13-valent Conjugate Vaccine Sales Share by Country (2021-2032) Figure 60. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 61. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales Share by Type (2021-2032) Figure 62. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 63. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales Share by Application (2021-2032) Figure 64. SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 65. SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales Share by Country (2021-2032) Figure 66. Pneumococcal 13-valent Conjugate Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Pneumococcal 13-valent Conjugate Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 0.5ml
  • Other
Applications
  • Hospital
  • Clinic
Companies covered
  • Pfizer
  • BIOKANGTAI
  • Walvax

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pneumococcal 13-valent Conjugate Vaccine Market by Type
  3. 1.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 0.5ml
  5. 1.2.3 Other
  6. 1.3 Pneumococcal 13-valent Conjugate Vaccine Market by Application
  7. 1.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Pneumococcal 13-valent Conjugate Vaccine Market Dynamics
  1. 2.1 Pneumococcal 13-valent Conjugate Vaccine Industry Trends
  2. 2.2 Pneumococcal 13-valent Conjugate Vaccine Industry Drivers
  3. 2.3 Pneumococcal 13-valent Conjugate Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumococcal 13-valent Conjugate Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region
  3. 3.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region
  9. 3.4.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Manufacturers
  6. 4.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Pneumococcal 13-valent Conjugate Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Pneumococcal 13-valent Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Pneumococcal 13-valent Conjugate Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Pneumococcal 13-valent Conjugate Vaccine Tier 1, Tier 2, and Tier 3
5 Pneumococcal 13-valent Conjugate Vaccine Market by Type
  1. 5.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type
  2. 5.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type
  6. 5.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Pneumococcal 13-valent Conjugate Vaccine Price by Type
6 Pneumococcal 13-valent Conjugate Vaccine Market by Application
  1. 6.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application
  2. 6.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application
  6. 6.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Pneumococcal 13-valent Conjugate Vaccine Price by Application
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 BIOKANGTAI
  8. 7.2.1 BIOKANGTAI Company Information
  9. 7.2.2 BIOKANGTAI Business Overview
  10. 7.2.3 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  12. 7.2.5 BIOKANGTAI Recent Developments
  13. 7.3 Walvax
  14. 7.3.1 Walvax Company Information
  15. 7.3.2 Walvax Business Overview
  16. 7.3.3 Walvax Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  18. 7.3.5 Walvax Recent Developments
8 North America
  1. 8.1 North America Pneumococcal 13-valent Conjugate Vaccine Market Size by Type
  2. 8.1.1 North America Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Pneumococcal 13-valent Conjugate Vaccine Price by Type (2021-2032)
  5. 8.2 North America Pneumococcal 13-valent Conjugate Vaccine Market Size by Application
  6. 8.2.1 North America Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Pneumococcal 13-valent Conjugate Vaccine Price by Application (2021-2032)
  9. 8.3 North America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
  10. 8.3.1 North America Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Pneumococcal 13-valent Conjugate Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Pneumococcal 13-valent Conjugate Vaccine Market Size by Type
  2. 9.1.1 Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Pneumococcal 13-valent Conjugate Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Pneumococcal 13-valent Conjugate Vaccine Market Size by Application
  6. 9.2.1 Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Pneumococcal 13-valent Conjugate Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
  10. 9.3.1 Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Pneumococcal 13-valent Conjugate Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Pneumococcal 13-valent Conjugate Vaccine Market Size by Type
  2. 10.1.1 China Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Pneumococcal 13-valent Conjugate Vaccine Price by Type (2021-2032)
  5. 10.2 China Pneumococcal 13-valent Conjugate Vaccine Market Size by Application
  6. 10.2.1 China Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Pneumococcal 13-valent Conjugate Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pneumococcal 13-valent Conjugate Vaccine Market Size by Type
  2. 11.1.1 Asia Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Pneumococcal 13-valent Conjugate Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Pneumococcal 13-valent Conjugate Vaccine Market Size by Application
  6. 11.2.1 Asia Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Pneumococcal 13-valent Conjugate Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
  10. 11.3.1 Asia Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Pneumococcal 13-valent Conjugate Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pneumococcal 13-valent Conjugate Vaccine Market Size by Type
  2. 12.1.1 SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Pneumococcal 13-valent Conjugate Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Pneumococcal 13-valent Conjugate Vaccine Market Size by Application
  6. 12.2.1 SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Pneumococcal 13-valent Conjugate Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
  10. 12.3.1 SAMEA Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Pneumococcal 13-valent Conjugate Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Pneumococcal 13-valent Conjugate Vaccine Value Chain Analysis
  2. 13.1.1 Pneumococcal 13-valent Conjugate Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Pneumococcal 13-valent Conjugate Vaccine Production Mode & Process
  6. 13.2 Pneumococcal 13-valent Conjugate Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Pneumococcal 13-valent Conjugate Vaccine Distributors
  9. 13.2.3 Pneumococcal 13-valent Conjugate Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst